FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAgenus Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AGEN
Agenus Inc. Stock AnalysisComprehensive stock analysis for Agenus Inc. (AGEN) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAGEN
AGEN
Agenus Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AGEN
  1. Home
  2. Stocks
  3. Agenus Inc.

Agenus Inc.

🇺🇸AGEN•NASDAQ

Agenus Inc.

🇺🇸AGEN•NASDAQ
Market cap
$289.58M
Sentiment

Your view on AGEN

Mkt Cap
$289.58M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Agenus Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Garo H. Armen
Headquarters
3 Forbes Road, Lexington, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Garo H. Armen
Headquarters
3 Forbes Road, Lexington, MA, US
Description

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.

The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody.

In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks.

It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Agenus Inc. from FRC's valuation model, read against the market price. AGEN last traded at $6.40, 8.6× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Agenus Inc.. Starting points for Agenus Inc.: P/E 8.6, EPS $0.49, beta 1.52 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Agenus Inc.. Agenus Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Agenus Inc.. Trailing twelve-month EPS for Agenus Inc. stands at $0.49. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 19, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$25.00

average of analysts' targets

 

$25.00

Low $25.00

Median $25.00

High $25.00

 

Analyst Ratings

Buy3 firms, last 12 months
  • Strong Buy0
  • Buy3
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate-$0.17-$0.23$0.63-$0.54
Low estimate-$0.17-$0.23$0.58-$0.84
High estimate-$0.17-$0.22$0.68-$0.23
No. of analysts1122
Year-ago EPS$0.561$1.021-$0.001—
Growth————

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$31.07M$25.45M$130.95M$121.30M
Low estimate$30.91M$25.32M$130.50M$96.81M
High estimate$31.24M$25.58M$131.40M$145.79M
No. of analysts1122
Year-ago revenue$34.20M$33.74M$114.20M—
Growth-9.1%-24.6%+14.7%—
Recent analyst actions15 rating and price-target changes, latest Nov 9, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 19, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Agenus Inc.. Agenus Inc. has reported as a listed company since 2000. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold AGEN20 companies · 8 funds
Compare AGEN with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ABOSAcumen Pharmaceuticals, Inc.Biotechnology$14M
  • FATEFate Therapeutics, Inc.Biotechnology$122M
  • HURATuHURA Biosciences, Inc.Biotechnology$87M
  • INOInovio Pharmaceuticals, Inc.Biotechnology$117M
  • IRDOpus Genetics, Inc.Biotechnology$326M
  • PLRXPliant Therapeutics, Inc.Biotechnology$41M
  • SEERSeer, Inc.Biotechnology$80M
  • TTRXTurn Therapeutics Inc.Biotechnology$272M

More Biotechnology companies

  • SGMTSagimet Biosciences Inc.NASDAQ$711M
  • SGPSpyGlass Pharma, Inc. Common StockNASDAQ$993M
  • SHJBFShanghai Junshi Biosciences Co., Ltd.OTC$4.1B
  • SIGYSigyn Therapeutics, Inc.OTC
  • SILOSilo Pharma, Inc.NASDAQ$2M
  • SIONSionna Therapeutics, Inc.NASDAQ$134M
  • SKYESkye Bioscience, Inc.NASDAQ$4M
  • SLBTSL Science Holding LtdNASDAQ$370M
  • SLDBSolid Biosciences Inc.NASDAQ$709M
  • SLGLSol-Gel Technologies Ltd.NASDAQ$175M
  • SLNSilence Therapeutics plcNASDAQ$936M
  • SLNCFSilence Therapeutics plcOTC$227M

ETFs holding Agenus Inc.

% of the fund

  • IWMiShares Russell 2000 ETF$76.6B in assets0.01%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
  • VXFVanguard Extended Market ETF$30.2B in assets0.00%
  • IWNiShares Russell 2000 Value ETF$13.9B in assets0.01%
  • QQQSInvesco NASDAQ Future Gen 200 ETF$20M in assets0.51%
  • VMO.TOVanguard Global Momentum Factor ETF$477M in assets0.06%
  • VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.01%
  • RSSLGlobal X - Russell 2000 ETF$1.4B in assets0.01%

Largest holders first, then the funds most concentrated in AGEN.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Agenus Inc., and how their positions are changing. At a $289.6M market value, institutional positions materially move Agenus Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Agenus Inc. executives and directors. Shares of Agenus Inc. have traded between $1.38 and $7.34 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Agenus Inc.. Coverage tracks Agenus Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Agenus Inc.

AGEN Analysis
Fair
Past5
Growth1
Health1
Profit1
Value4

News

Latest Market News